Symptoms and General Pathology

All Conditions

Infections

Respiratory Tract (Lung and Bronchial) Diseases

Emergencies

COVID-19

Pneumonia

Pneumonia, Viral

Communicable Diseases

Respiratory Tract Infections

Virus Diseases

Coronavirus Infections

Coronaviridae Infections

Nidovirales Infections

RNA Virus Infections

Lung Diseases

Respiratory Tract Diseases

Pierce Chow, MD, PhD

This study aims to look at the impact on patient outcomes arising from measures implemented during the COVID-19 pandemic. The information and knowledge from this study will be useful for the management and allocation of hospital resources and patients in tne event of a disease outbreak.

Impact of Measures Taken to Contain COVID-19 on Hospital Surgical Care Services and Clinical Outcomes

These patients are classified according to the institution, type of surgical procedures, the medical condition and the dates of surgical treatment. The study will be compared across four time periods.

The study focus on surgical indices for selected high-volume cancer and non-cancer diagnoses over the period 1st January2020 to 31 December 2020 and compare them with similar indices across the same period of time in the preceding 3 years in particular, for the following surgical procedures:

1. Surgeries for the following cancer diagnoses:

   1. breast cancer, \[XIV- N60, no malignancy\], \[Malignant, IINeoplasms- C50\], colorectal cancer, \[C18, 19, 20\],
   2. hepatocellular carcinoma, \[C22\]
2. Selected non-cancer surgeries:

   1. Cholecystectomy
   2. Abdominal hernia repair

National Medical Research Council (NMRC), Singapore

National Cancer Centre, Singapore

Neoplasms

Lung Neoplasms

Inflammation

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung neoplasms irrespective of stage and histology

Anne-Pascale Meert, MD, PhD

Systemic inflammation is a potential prognostic factor in cancer. Inflammation scores as the Glasgow score have been tested in cancer and specifically in lung cancer patients. The aim of the study is to look at the prognostic and predictive value of inflammation during cancer evolution, on the risk of complications leading to ICU admission and the risk of death.

Patients with newly diagnosed lung cancer will be eligible. All patients will have a blood sampling allowing testing inflammation and cytokine analyses at diagnosis, during work-up and in case of complication.

Has Inflammation a Significant Implication in Lung Cancer Evolution?

L'Inflammation A-t-elle Une Implication Significative Dans l'évolution du Cancer Bronchique?

Recording any complication leading to consultation at the emergency department or admission into the intensive care unit

Jules Bordet Institute

European Lung Cancer Working Party

Behaviors and Mental Disorders

Aggression

Disease Attributes

Conventional strategy: patients will be managed regardless of their PALLIA-10 score. The need for additional care, including palliative care, will be assessed by the team in charge of the patient, as per routine practice.

Experimental strategy: patients will be systematically referred to a palliative care team.

Patients randomized in the experimental arm will be systematically referred to a palliative care team.

A follow-up in palliative care will be initiated for all within a maximum of 15 days after the date of randomization.

Systematic referral to a palliative care team

Gisèle CHVETZOFF, MD, PhD

Julien GAUTIER

Gisèle CHVETZOFF, MD,PhD

Muriel THOMASO, MD

Carole BOULEUC, MD

Marie-Ange MASSIANI, MD

Aline HENRY, MD

Christine MATEUS, MD

This is a randomized, multicenter, prospective, phase III study conducted in daily emergency rooms of French Regional Comprehensive Cancer Centers.

In the standard arm, patients will be managed regardless of their PALLIA-10 score, following conventional strategy. In the experimental arm, patients will be systematically referred to a palliative care team.

This is a randomized, multicenter, prospective, phase III study conducted in daily emergency rooms of French Regional Comprehensive Cancer Centers.

All patients undergoing a visit in the daily emergency room of a participating center and who need for palliative management (PALLIA 10 score \> 3/10) will be considered for inclusion in the PALLU study. After signing the written informed consent, patients will be randomized (1:1 ratio) in one of the following arms:

* Standard arm : conventional strategy; patients will be managed regardless of their PALLIA-10 score. The need for additional care, including palliative care, will be assessed by the team in charge of the patient, as per routine practice.
* Experimental arm : experimental strategy; patients will be systematically referred to a palliative care team.

Randomization will be stratified according to the investigation center and pre-existing follow-up by pain management team.

The difference of intervention will lie in the fact that patients will be referred or not to a palliative care team but patients from the standard arm may receive palliative care as deemed necessary by the medical oncology team. In this case, the content of palliative care for patients included in both groups will be identical.

The end of the study will be the Last Patient Last Visit (LPLV), defined as the date of the 6-month visit of the last patient still alive or when the 192nd death has occurred, whichever occurs first.

Randomization (ratio 1:1) will be stratified according to the investigation center and pre-existing follow-up by pain management team.

Efficacy of a Systematic Referral to Palliative Care of Patients Who Need for Palliative Care During an Unscheduled Visit in Comprehensive Anticancer Centers

A Randomized Comparative Prospective Multicenter Study of the Efficacy of a Systematic Referral to Palliative Care of Patients Who Need for Palliative Care During an Unscheduled Visit in Comprehensive Anticancer Centers

Percentage and number of patients who meet at least one of the following criteria :

* More than 1 hospitalization in the last 30 days of life;
* More than 1 visit in an emergency unit in the last 30 days of life;
* More than 14 days in hospital in the last 30 days of life;
* Hospitalization in a resuscitation unit in the last 30 days of life;
* Treatment with chemotherapy in the last 14 days of life;
* New chemotherapy regimen starting in the last 30 days of life;
* Patients dying in an acute care setting.

Percentage and number of patients having more than 1 hospitalization in the last 30 days of life

Percentage and number of patients having more than 1 visit in an emergency unit in the last 30 days of life

Percentage and number of patients having more than 14 days in hospital in the last 30 days of life

Percentage and number of patients having a hospitalization in a resuscitation unit in the last 30 days of life

Percentage and number of patients having a treatment with chemotherapy in the last 14 days of life

Percentage and number of patients having a new chemotherapy regimen starting in the last 30 days of life

Percentage and number of patients dying in an acute care setting

Medical resources mobilized in terms of palliative care (psychologist, social worker, nutritional counselling, etc.) will be described for the interventional group in terms of number and percentage of patients with at least one consultation with each specialist

The total score ranges from 0 and 28, with a higher score indicates better quality of life. Scores will be described per randomized group at each measurement time (inclusion,3 months and 6 months) using same criteria as for other quantitative variables (number of observations, mean, standard deviation, median, minimum and maximum values).

One score is generated for anxiety and one score for depression on a 0 to 21 points, with a higher score indicates higher level of trouble. Scores will be described per randomized group at each measurement time (inclusion,3 months and 6 months) using same criteria as for other quantitative variables (number of observations, mean, standard deviation, median, minimum and maximum values). Number and percentage of patients without anxiety or depression trouble (i.e. with a score of 7 or lower), moderate trouble (score between 8 to 10) and severe trouble (score of 11 or more) will be reported.

Pain, tiredness, drowsiness, nausea, lack of appetite, depression, anxiety, shortness of breath, and wellbeing and patient-specific symptoms are each described on a scale ranging from 0 to 10 (10 being the worst). The mean change in symptoms will be estimated from baseline and at each follow-up time. The ESAS symptom scores will be calculated according to the authors' recommendations and described per randomized group at each time point by mean, standard deviation, median and range.

Hospital and type of unit or home will be described per randomized group

Defined as the time from the date of inclusion to the date of death due to any cause.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Impact of Measures Taken to Contain COVID-19 on Hospital Surgical Care Services and Clinical Outcomes	NCT04961489	Surgery		21 Years - 100 Years	National Cancer Centre, Singapore
Impact of Measures Taken to Contain COVID-19 on Hospital Surgical Care Services and Clinical Outcomes	NCT04961489	Surgery		21 Years - 100 Years	National Cancer Centre, Singapore
Has Inflammation a Significant Implication in Lung Cancer Evolution?	NCT02484872	Lung Neoplasms		18 Years -	European Lung Cancer Working Party
Efficacy of a Systematic Referral to Palliative Care of Patients Who Need for Palliative Care During an Unscheduled Visit in Comprehensive Anticancer Centers	NCT06150027	Cancer Emergencies	Systematic refe...	18 Years -	Centre Leon Berard

Spots Global Cancer Trial Database for emergency

Every month we try and update this database with for emergency cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for emergency

Every month we try and update this database with for emergency cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for emergency cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.